NCT04297085 Prospective Cohort Study on the Determinants of Venous THromboembolic Recurrence
| NCT ID | NCT04297085 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Brest |
| Condition | Thromboembolic Venous Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 3,400 participants |
| Start Date | 2020-05-28 |
| Primary Completion | 2050-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 3,400 participants in total. It began in 2020-05-28 with a primary completion date of 2050-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The main objective of the BREIZH-Cohorte study is to determine the incidence of recurrent short, medium and long-term thromboembolic venous disease as well as risk factors for recurrence in two specific populations: patients under 50 years of age, men and women (5 year recurrence), as well as cancer patients (all ages) (1 year recurrence).
Eligibility Criteria
Inclusion Criteria: * Subject aged 18 or over, or a minor with the consent of the parents and the minor, presenting with a thromboembolic venous disease * 50 and under or any age if active cancer * Affiliated to social security * Accepting to participate in the study. Exclusion Criteria: * Inability to communicate (comprehension disorder). * Refusal to participate.
Contact & Investigator
Francis COUTURAUD, MD, PHD
PRINCIPAL INVESTIGATOR
EA3878 (GETBO), Brest University Hospital in France
Frequently Asked Questions
Who can join the NCT04297085 clinical trial?
This trial is open to participants of all sexes, studying Thromboembolic Venous Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04297085 currently recruiting?
Yes, NCT04297085 is actively recruiting participants. Contact the research team at francis.couturaud@chu-brest.fr for enrollment information.
Where is the NCT04297085 trial being conducted?
This trial is being conducted at Brest, France, Brest, France, Morlaix, France, Quimper, France.
Who is sponsoring the NCT04297085 clinical trial?
NCT04297085 is sponsored by University Hospital, Brest. The principal investigator is Francis COUTURAUD, MD, PHD at EA3878 (GETBO), Brest University Hospital in France. The trial plans to enroll 3,400 participants.